Nextbiomedical Co. Ltd. engages in the development of therapeutics based on polymer and drug delivery system technologies. Its products include Nexpowder: Hemostatic Systems for Endoscopy, Nexsphere: Resorbable Gelatin Microspheres for Tailored Embolization, Nexsphere-F: Fast-Resorbable Gelatin Microspheres for Musculoskeletal Embolization and NexGel: Resorbable Gelatin Microparticle for Embolization. The company was founded on August 1, 2014 and is headquartered in Incheon, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company